https://www.selleckchem.com/products/OSI-906.html
Erenumab, a monoclonal antibody against the calcitonin gene-related peptide (CGRP) receptor, is registered for migraine prevention. Compared to other conventional migraine prevention medicines (i.e. topiramate, betablockers and amitriptyline) erenumab has better tolerability. Impaired hemostasis has not been reported previously. Here, we report the first case of an increased tendency to bruise in a migraine patient treated with erenumab. A 41-year old female migraine patient was treated with erenumab for 12months, which led to a signifi
Like
Comment
Share
